Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation.

Sriram G, Reichman C, Tunceroglu A, Kaushal N, Saleh T, Machida K, Mayer B, Ge Q, Li J, Hornbeck P, Kalodimos CG, Birge RB.

Oncogene. 2011 Nov 17;30(46):4645-55. doi: 10.1038/onc.2011.170. Epub 2011 May 23.

2.

Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk.

Sriram G, Jankowski W, Kasikara C, Reichman C, Saleh T, Nguyen KQ, Li J, Hornbeck P, Machida K, Liu T, Li H, Kalodimos CG, Birge RB.

Oncogene. 2015 Aug 6;34(32):4260-9. doi: 10.1038/onc.2014.361. Epub 2014 Nov 10.

3.

Crk family adaptor proteins trans-activate c-Abl kinase.

Shishido T, Akagi T, Chalmers A, Maeda M, Terada T, Georgescu MM, Hanafusa H.

Genes Cells. 2001 May;6(5):431-40.

4.

Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide.

Donaldson LW, Gish G, Pawson T, Kay LE, Forman-Kay JD.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14053-8. Epub 2002 Oct 16.

5.

Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II.

Zvara A, Fajardo JE, Escalante M, Cotton G, Muir T, Kirsch KH, Birge RB.

Oncogene. 2001 Feb 22;20(8):951-61.

6.
7.

Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain.

Reichman C, Singh K, Liu Y, Singh S, Li H, Fajardo JE, Fiser A, Birge RB.

Oncogene. 2005 Dec 8;24(55):8187-99.

PMID:
16158059
8.

A potential SH3 domain-binding site in the Crk SH2 domain.

Anafi M, Rosen MK, Gish GD, Kay LE, Pawson T.

J Biol Chem. 1996 Aug 30;271(35):21365-74.

9.

The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.

Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD.

Oncogene. 1996 Feb 15;12(4):839-46.

PMID:
8632906
10.

c-Abl kinase regulates the protein binding activity of c-Crk.

Feller SM, Knudsen B, Hanafusa H.

EMBO J. 1994 May 15;13(10):2341-51.

11.

Reciprocal regulation of Abl kinase by Crk Y251 and Abi1 controls invasive phenotypes in glioblastoma.

Kumar S, Lu B, Dixit U, Hossain S, Liu Y, Li J, Hornbeck P, Zheng W, Sowalsky AG, Kotula L, Birge RB.

Oncotarget. 2015 Nov 10;6(35):37792-807. doi: 10.18632/oncotarget.6096.

12.
13.
14.

Crk adaptor protein-induced phosphorylation of Gab1 on tyrosine 307 via Src is important for organization of focal adhesions and enhanced cell migration.

Watanabe T, Tsuda M, Makino Y, Konstantinou T, Nishihara H, Majima T, Minami A, Feller SM, Tanaka S.

Cell Res. 2009 May;19(5):638-50. doi: 10.1038/cr.2009.40.

PMID:
19350053
15.
16.

Phosphorylation of c-Crk II on the negative regulatory Tyr222 mediates nerve growth factor-induced cell spreading and morphogenesis.

Escalante M, Courtney J, Chin WG, Teng KK, Kim JI, Fajardo JE, Mayer BJ, Hempstead BL, Birge RB.

J Biol Chem. 2000 Aug 11;275(32):24787-97.

17.
18.

Interaction in vitro of the product of the c-Crk-II proto-oncogene with the insulin-like growth factor I receptor.

Koval AP, Blakesley VA, Roberts CT Jr, Zick Y, Leroith D.

Biochem J. 1998 Mar 1;330 ( Pt 2):923-32.

19.

Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK.

Jung JH, Pendergast AM, Zipfel PA, Traugh JA.

Biochemistry. 2008 Jan 22;47(3):1094-104. Epub 2007 Dec 28.

PMID:
18161990
20.

Supplemental Content

Support Center